Dupilumab
Also known as Dupixent®, REGN668, SAR231893
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13 receptor signalling (IL-4R, IL-13R), used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease.
Key facts
- Drug.type
- mab
- Drug.image
- Dupilumab fab binding to IL-4.png
- Drug.alt
- 3D structure of dupilumab's antigen binding fragment complexed with a human IL-4 receptor sub-unit alpha
- Drug.caption
- Dupilumab antigen binding fragment (orange and green) bound to a human IL-4 receptor alpha (purple)
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Interleukin 4 (IL4) receptor alpha
- Drug.tradename
- Dupixent
- Drug.MedlinePlus
- a617021
- Drug.DailyMedID
- Dupilumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous